ktyan

Hey everyone, I'm currently researching therapeutic monoclonal antibodies, like trastuzumab for breast cancer. There's one mechanism of action that is particularly interesting, but also poses a few questions that I can't find the answers to. When trastuzumab binds the HER2 antigen on cancer cells, it can induce antibody-dependent cellular cytotoxicity by recruiting effector cells which release cytotoxic agents like granzyme or perforin. In this case, NK cells have Fc receptors that bind to the Fc domain of trastuzumab. My question is, how does trastuzumab recruit the effector cells in the first place? How does it attract NK cells to attach to its Fc domain? Thanks!